Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19 - CISMeF
Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19NCIt concept
Preferred Label : Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T Lymphocytes BinD19;
NCIt synonyms : Autologous Anti-CD19 CAR TCR-zeta/4-1BB-transduced T-cells BinD19;
NCIt definition : Autologous T-lymphocytes that have been transduced with a lentiviral vector to express
a T-cell receptor (TCR) consisting of a single chain variable fragment (scFv) of anti-CD19
coupled to the co-stimulatory molecule 4-1BB (CD137) and to the cytoplasmic portion
of the zeta chain of the human T-cell receptor (CD3zeta), with potential immunostimulating
and antineoplastic activities. Upon transfusion, the autologous anti-CD19 CAR TCR-zeta/4-1BB-transduced
T-lymphocytes BinD19 target and bind to CD19-expressing neoplastic B-cells. This results
in a cytotoxic T-lymphocyte (CTL) response against CD19-expressing tumor cells, the
release of cytotoxic molecules and tumor cell lysis. CD19, cluster of differentiation
19, is a B-cell-specific cell surface antigen overexpressed in B-cell lineage tumors.
Incorporation of the costimulatory signaling domains increases human T-cell function,
expansion, and survival.;